Table 1 Characteristics of patients taking standard (150 mg) or reduced (75 mg) dose dabigatran
|  | Reduced dose (75 mg twice daily) | Standard Dose (150 mg twice daily) | P-value |
|---|---|---|---|
Total number of patients | 1455 | 6580 | Â |
Age Category, years |  |  | < 0.001 |
 65–69 | 7.1% | 18.0% |  |
 70 to 74 | 13.7% | 26.8% |  |
 75 to 79 | 18.8% | 25.4% |  |
 80 to 84 | 26.0% | 18.1% |  |
 85 to 89 | 16.8% | 7.1% |  |
 90 or over | 17.5% | 4.7% |  |
Sex |  |  | < 0.001 |
 Female | 56.3% | 47.9% |  |
 Male | 43.7% | 52.1% |  |
Race Category |  |  | < 0.001 |
 White | 84.1% | 87.5% |  |
 Black | 10.2% | 6.9% |  |
 Hispanic | 2.5% | 1.7% |  |
 Asian | 1.4% | 0.6% |  |
 Other | 1.9% | 3.2% |  |
 Smoking | 14.0% | 16.7% | 0.01 |
 Alcohol use | 2.0% | 2.3% | < 0.001 |
Weight Category (based on ICD-9 and ICD-10 codes for BMI Category) |  |  | < 0.001 |
 Under-Weight | 1.2% | 0.6% |  |
 Healthy or Overweight | 10.1% | 8.0% |  |
 Obese or Severe Obese | 20.1% | 23.9% |  |
 Not available | 68.5% | 67.5% |  |
Comorbid Conditions | |||
 Prior Stroke | 26.8% | 24.4% | 0.06 |
 Prior major bleeding from Diagnosis | 26.7% | 24.5% | 0.07 |
 Gastrointestinal bleeding | 0 | 13.0% | 0.24 |
 Cerebral bleeding | 0 | 0.8% | 0.7 |
 Diabetes | 50.7% | 48.9% | 0.2 |
 Prior AMI | 8.0% | 5.2% | < 0.001 |
 Liver Disease | 3.4% | 2.6% | 0.13 |
 Heart Failure | 48.6% | 31.3% | < 0.001 |
 Hypertension | 96.0% | 93.4% | < 0.001 |
 Ischemic cardiomyopathy | 55.5% | 48.0% | < 0.001 |
 Pulmonary | 16.6% | 11.4% | < 0.001 |
 COPD | 36.4% | 31.8% | < 0.001 |
 Transfusion from Procedure | 3.8% | 2.7% | 0.02 |
 Revascularization | 17.3% | 15.0% | 0.03 |
 Implantable Devices | 16.9% | 13.8% | 0.002 |
 Valve Disease | 44.7% | 40.3% | 0.002 |
Renal Disease (ICD-9 and ICD-10 codes) |  |  | < 0.001 |
 None or Mild (Stage I, II) | 53.4% | 81.7% |  |
 Moderate (Stage III) | 36.0% | 16.5% |  |
 Severe (Stage IV, V) | 10.6% | 1.7% |  |
Concurrent Drugs (+/− 90 days of initiating DOAC) | |||
 SSRI/SNRI | 33.5% | 31.0% | 0.05 |
 Strong and moderate P-GP inhibitors | 21.4% | 22.7% | 0.28 |
 P-GP inducers | 16.4% | 18.8% | 0.03 |
 Strong P-GP and CYP3A4 dual inhibitors | 22.7% | 22.5% | 0.8 |
 P-GP and CYP3A4 inducers | 16.4% | 18.8% | 0.03 |
 ACE inhibitors | 70.1% | 68.0% | 0.12 |
 Warfarin | 20.8% | 25.0% | < 0.001 |
 Angiotensin receptor blockers | 41.0% | 39.3% | 0.2 |
 Beta blockers | 92.1% | 89.1% | < 0.001 |
 Calcium channel blockers | 66.8% | 63.8% | 0.03 |
 Digoxin | 31.1% | 29.4% | 0.2 |
 Proton pump inhibitors | 60.5% | 56.4% | 0.004 |
 NSAIDs | 49.6% | 51.2% | 0.29 |
 Antiplatelets | 32.0% | 26.5% | < 0.001 |
 Insulin | 17.0% | 12.9% | < 0.001 |
 Statins | 79.6% | 79.4% | 0.86 |
 Antiarrhythmics | 47.3% | 48.0% | 0.6 |
Estimated Glomerular Filtration rate (ml/min/1.73 m2) |  |  | < 0.001 |
  < 30 | 12.3% | 2.5% |  |
 30–60 | 62.2% | 45.8% |  |
 60–90 | 23.8% | 46.0% |  |
> = 90 | 1.8% | 5.7% |  |
CCI(Charlson Comorbodity Index), mean (standard deviation) | 5.52 (3.75) | 4.17(3.47) | < 0.001 |